Soy isoflavone supplementation for breast cancer risk reduction

A randomized phase ii trial

Seema A. Khan, Robert T. Chatterton, Nancy Michel, Michelle Bryk, Oukseub Lee, David Ivancic, Richard Heinz, Carola M. Zalles, Irene B. Helenowski, Borko D. Jovanovic, Adrian A. Franke, Maarten C. Bosland, Jun Wang, Nora M. Hansen, Kevin P. Bethke, Alexander Dew, Margerie Coomes, Raymond Bergan

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Soy isoflavone consumption may protect against breast cancer development. We conducted a phase IIB trial of soy isoflavone supplementation to examine its effect on breast epithelial proliferation and other biomarkers in the healthy high-risk breast. One hundred and twenty-six consented women underwent a random fine-needle aspiration (rFNA); those with 4,000 or more epithelial cells were randomized to a double-blind 6-month intervention of mixed soy isoflavones (PTIG-2535) or placebo, followed by repeat rFNA. Cells were examined for Ki-67 labeling index and atypia. Expression of 28 genes related to proliferation, apoptosis, and estrogenic effect was measured using quantitative reverse transcriptase PCR. Hormone and protein levels were measured in nipple aspirate fluid (NAF). All statistical tests were two-sided. Ninety-eight women were evaluable for Ki-67 labeling index. In 49 treated women, the median Ki-67 labeling index was 1.18 at entry and 1.12 post intervention, whereas in 49 placebo subjects, it was 0.97 and 0.92 (P for between-group change: 0.32). Menopausal stratification yielded similar results between groups, but within premenopausal soy-treated women, Ki-67 labeling index increased from 1.71 to 2.18 (P = 0.04). We saw no treatment effect on cytologic atypia or NAF parameters. There were significant increases in the expression of 14 of 28 genes within the soy, but not the control group, without significant between-group differences. Plasma genistein values showed excellent compliance. A 6-month intervention of mixed soy isoflavones in healthy, high-risk adult Western women did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention and a possible adverse effect in premenopausal women.

Original languageEnglish (US)
Pages (from-to)309-319
Number of pages11
JournalCancer Prevention Research
Volume5
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Isoflavones
Risk Reduction Behavior
Breast Neoplasms
Nipple Aspirate Fluid
Breast
Fine Needle Biopsy
Placebos
Genistein
Reverse Transcriptase Polymerase Chain Reaction
Compliance
Estrogens
Biomarkers
Epithelial Cells
Hormones
Apoptosis
Gene Expression
Control Groups
Genes
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Soy isoflavone supplementation for breast cancer risk reduction : A randomized phase ii trial. / Khan, Seema A.; Chatterton, Robert T.; Michel, Nancy; Bryk, Michelle; Lee, Oukseub; Ivancic, David; Heinz, Richard; Zalles, Carola M.; Helenowski, Irene B.; Jovanovic, Borko D.; Franke, Adrian A.; Bosland, Maarten C.; Wang, Jun; Hansen, Nora M.; Bethke, Kevin P.; Dew, Alexander; Coomes, Margerie; Bergan, Raymond.

In: Cancer Prevention Research, Vol. 5, No. 2, 02.2012, p. 309-319.

Research output: Contribution to journalArticle

Khan, SA, Chatterton, RT, Michel, N, Bryk, M, Lee, O, Ivancic, D, Heinz, R, Zalles, CM, Helenowski, IB, Jovanovic, BD, Franke, AA, Bosland, MC, Wang, J, Hansen, NM, Bethke, KP, Dew, A, Coomes, M & Bergan, R 2012, 'Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase ii trial', Cancer Prevention Research, vol. 5, no. 2, pp. 309-319. https://doi.org/10.1158/1940-6207.CAPR-11-0251
Khan, Seema A. ; Chatterton, Robert T. ; Michel, Nancy ; Bryk, Michelle ; Lee, Oukseub ; Ivancic, David ; Heinz, Richard ; Zalles, Carola M. ; Helenowski, Irene B. ; Jovanovic, Borko D. ; Franke, Adrian A. ; Bosland, Maarten C. ; Wang, Jun ; Hansen, Nora M. ; Bethke, Kevin P. ; Dew, Alexander ; Coomes, Margerie ; Bergan, Raymond. / Soy isoflavone supplementation for breast cancer risk reduction : A randomized phase ii trial. In: Cancer Prevention Research. 2012 ; Vol. 5, No. 2. pp. 309-319.
@article{99bdeb7a953e475db9bbbfd0d4f8f031,
title = "Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase ii trial",
abstract = "Soy isoflavone consumption may protect against breast cancer development. We conducted a phase IIB trial of soy isoflavone supplementation to examine its effect on breast epithelial proliferation and other biomarkers in the healthy high-risk breast. One hundred and twenty-six consented women underwent a random fine-needle aspiration (rFNA); those with 4,000 or more epithelial cells were randomized to a double-blind 6-month intervention of mixed soy isoflavones (PTIG-2535) or placebo, followed by repeat rFNA. Cells were examined for Ki-67 labeling index and atypia. Expression of 28 genes related to proliferation, apoptosis, and estrogenic effect was measured using quantitative reverse transcriptase PCR. Hormone and protein levels were measured in nipple aspirate fluid (NAF). All statistical tests were two-sided. Ninety-eight women were evaluable for Ki-67 labeling index. In 49 treated women, the median Ki-67 labeling index was 1.18 at entry and 1.12 post intervention, whereas in 49 placebo subjects, it was 0.97 and 0.92 (P for between-group change: 0.32). Menopausal stratification yielded similar results between groups, but within premenopausal soy-treated women, Ki-67 labeling index increased from 1.71 to 2.18 (P = 0.04). We saw no treatment effect on cytologic atypia or NAF parameters. There were significant increases in the expression of 14 of 28 genes within the soy, but not the control group, without significant between-group differences. Plasma genistein values showed excellent compliance. A 6-month intervention of mixed soy isoflavones in healthy, high-risk adult Western women did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention and a possible adverse effect in premenopausal women.",
author = "Khan, {Seema A.} and Chatterton, {Robert T.} and Nancy Michel and Michelle Bryk and Oukseub Lee and David Ivancic and Richard Heinz and Zalles, {Carola M.} and Helenowski, {Irene B.} and Jovanovic, {Borko D.} and Franke, {Adrian A.} and Bosland, {Maarten C.} and Jun Wang and Hansen, {Nora M.} and Bethke, {Kevin P.} and Alexander Dew and Margerie Coomes and Raymond Bergan",
year = "2012",
month = "2",
doi = "10.1158/1940-6207.CAPR-11-0251",
language = "English (US)",
volume = "5",
pages = "309--319",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Soy isoflavone supplementation for breast cancer risk reduction

T2 - A randomized phase ii trial

AU - Khan, Seema A.

AU - Chatterton, Robert T.

AU - Michel, Nancy

AU - Bryk, Michelle

AU - Lee, Oukseub

AU - Ivancic, David

AU - Heinz, Richard

AU - Zalles, Carola M.

AU - Helenowski, Irene B.

AU - Jovanovic, Borko D.

AU - Franke, Adrian A.

AU - Bosland, Maarten C.

AU - Wang, Jun

AU - Hansen, Nora M.

AU - Bethke, Kevin P.

AU - Dew, Alexander

AU - Coomes, Margerie

AU - Bergan, Raymond

PY - 2012/2

Y1 - 2012/2

N2 - Soy isoflavone consumption may protect against breast cancer development. We conducted a phase IIB trial of soy isoflavone supplementation to examine its effect on breast epithelial proliferation and other biomarkers in the healthy high-risk breast. One hundred and twenty-six consented women underwent a random fine-needle aspiration (rFNA); those with 4,000 or more epithelial cells were randomized to a double-blind 6-month intervention of mixed soy isoflavones (PTIG-2535) or placebo, followed by repeat rFNA. Cells were examined for Ki-67 labeling index and atypia. Expression of 28 genes related to proliferation, apoptosis, and estrogenic effect was measured using quantitative reverse transcriptase PCR. Hormone and protein levels were measured in nipple aspirate fluid (NAF). All statistical tests were two-sided. Ninety-eight women were evaluable for Ki-67 labeling index. In 49 treated women, the median Ki-67 labeling index was 1.18 at entry and 1.12 post intervention, whereas in 49 placebo subjects, it was 0.97 and 0.92 (P for between-group change: 0.32). Menopausal stratification yielded similar results between groups, but within premenopausal soy-treated women, Ki-67 labeling index increased from 1.71 to 2.18 (P = 0.04). We saw no treatment effect on cytologic atypia or NAF parameters. There were significant increases in the expression of 14 of 28 genes within the soy, but not the control group, without significant between-group differences. Plasma genistein values showed excellent compliance. A 6-month intervention of mixed soy isoflavones in healthy, high-risk adult Western women did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention and a possible adverse effect in premenopausal women.

AB - Soy isoflavone consumption may protect against breast cancer development. We conducted a phase IIB trial of soy isoflavone supplementation to examine its effect on breast epithelial proliferation and other biomarkers in the healthy high-risk breast. One hundred and twenty-six consented women underwent a random fine-needle aspiration (rFNA); those with 4,000 or more epithelial cells were randomized to a double-blind 6-month intervention of mixed soy isoflavones (PTIG-2535) or placebo, followed by repeat rFNA. Cells were examined for Ki-67 labeling index and atypia. Expression of 28 genes related to proliferation, apoptosis, and estrogenic effect was measured using quantitative reverse transcriptase PCR. Hormone and protein levels were measured in nipple aspirate fluid (NAF). All statistical tests were two-sided. Ninety-eight women were evaluable for Ki-67 labeling index. In 49 treated women, the median Ki-67 labeling index was 1.18 at entry and 1.12 post intervention, whereas in 49 placebo subjects, it was 0.97 and 0.92 (P for between-group change: 0.32). Menopausal stratification yielded similar results between groups, but within premenopausal soy-treated women, Ki-67 labeling index increased from 1.71 to 2.18 (P = 0.04). We saw no treatment effect on cytologic atypia or NAF parameters. There were significant increases in the expression of 14 of 28 genes within the soy, but not the control group, without significant between-group differences. Plasma genistein values showed excellent compliance. A 6-month intervention of mixed soy isoflavones in healthy, high-risk adult Western women did not reduce breast epithelial proliferation, suggesting a lack of efficacy for breast cancer prevention and a possible adverse effect in premenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=84863263259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863263259&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-11-0251

DO - 10.1158/1940-6207.CAPR-11-0251

M3 - Article

VL - 5

SP - 309

EP - 319

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -